Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
KIT
REST API REST API
Homo sapiens
KIT is differentially expressed in 250 experiments: 87 organism parts: cerebellum, liver, ... (85 more);, 133 disease states: normal, acute myeloid leukemia, ... (131 more);, 90 cell types 329 cell lines 18 compound treatments and 75 other conditions.
Synonyms SCFR, CD117, C-Kit, PBT
Orthologs kitb (Danio rerio)   kita (Danio rerio)   Kit (Mus musculus)   F1NKK2_CHICK (Gallus gallus)   KIT_BOVIN (Bos taurus)   Kit (Rattus norvegicus)   Pvr (Drosophila melanogaster)   NP_001135545.1 (Xenopus laevis)   KIT_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term positive regulation of JAK-STAT cascade, protein binding, negative regulation of programmed cell death, stem cell maintenance, cytokine-mediated signaling pathway, regulation of cell proliferation, extracellular space, positive regulation of cell proliferation, positive regulation of gene expression, membrane, peptidyl-tyrosine phosphorylation, spermatogenesis, male gonad development, protein tyrosine kinase activity, positive regulation of MAP kinase activity, transmembrane receptor protein tyrosine kinase signaling pathway, external side of plasma membrane, activation of MAPK activity, developmental pigmentation, hemopoiesis, ATP binding, germ cell programmed cell death, integral to plasma membrane, cytokine binding, spermatid development, receptor activity, nucleotide binding, protein serine/threonine kinase activity, transmembrane receptor protein tyrosine kinase activity, protein homodimerization activity, integral to membrane, cell surface, regulation of developmental pigmentation, response to radiation, signal transduction, protein kinase activity, intracellular protein kinase cascade, protease binding, myeloid leukocyte differentiation, positive regulation of tyrosine phosphorylation of Stat1 protein, receptor signaling protein tyrosine kinase activity, melanocyte differentiation, glycosphingolipid metabolic process, myeloid progenitor cell differentiation, lymphoid progenitor cell differentiation, pigmentation, positive regulation of tyrosine phosphorylation of Stat5 protein, positive regulation of MAPKKK cascade, stem cell factor receptor activity, positive regulation of tyrosine phosphorylation of Stat3 protein, protein autophosphorylation, protein phosphorylation, positive regulation of phospholipase C activity, positive regulation of phosphatidylinositol 3-kinase activity, positive regulation of phosphatidylinositol 3-kinase cascade, positive regulation of sequence-specific DNA binding transcription factor activity, vascular endothelial growth factor-activated receptor activity, mast cell differentiation, mast cell proliferation
InterPro Term Ig_sub, Immunoglobulin, Prot_kinase_cat_dom, Ig-like, Ig_sub2, Ig_I-set, Tyr_kinase_VEGFR_rcpt_N, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Tyr_kinase_CSF1/PDGF_rcpt, Se/Thr_kinase-like_dom
UniProt Accession B6E0M6, D5LXN2, Q8TCG9, B6DXN3, P10721, F5H8F8
Gene-Disease Assocation TESTICULAR TUMORS, LEUKEMIA, ACUTE MYELOID; AML, PIEBALD TRAIT; PBT, GASTROINTESTINAL STROMAL TUMOR; GIST
Search EB-eye ENSG00000157404
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-17189, E-GEOD-6573, E-MEXP-433, E-GEOD-2549, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-3860, E-GEOD-2450, E-GEOD-4717, E-MTAB-62, ... (30 experiments)

Factor Value U/D Experiments
HCC1954
2
E-GEOD-29119, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
HL-60
2
E-MTAB-37, E-GEOD-24147
SW480
2
E-MEXP-1014, E-MTAB-37
22Rv1
1
E-MTAB-37
YCC6
1
E-GEOD-15460
323 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-13909, ... (43 experiments)

Factor Value U/D Experiments
B cell
1
2
E-GEOD-3982, E-GEOD-13987
CD34+
2
E-AFMX-5, E-TABM-145
fibroblast
2
E-GEOD-3920, E-GEOD-3204
breast cancer
1
E-GEOD-29119
CD14+ monocyte
1
E-AFMX-5
germ cell
1
E-MTAB-25
84 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-MEXP-1121, E-GEOD-16363, ... (53 experiments)

Factor Value U/D Experiments
chronic lymphocytic leukemia
2
E-GEOD-2466, E-GEOD-6691
colon carcinoma
2
E-MTAB-62, E-MTAB-57
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
glioblastoma
1
2
E-GEOD-4290, E-MTAB-37, E-MEXP-567
acute monoblastic/monocytic leukemia
1
E-GEOD-1729
DiseaseState
1
E-MEXP-1243
127 more value(s).


Compound treatment

studied in E-TABM-782, E-GEOD-5824, E-GEOD-3720, E-GEOD-3140, E-GEOD-15811, ... (14 experiments)

Factor Value U/D Experiments
none
2
4
E-TABM-782, E-GEOD-412, E-GEOD-3140, E-GEOD-5099, E-GEOD-5824, ... (6 experiments)
placebo
1
E-MEXP-1335
AMP
1
E-MEXP-2285
actinomycin D
1
1
E-GEOD-6400
sapphyrin PCI-2050
1
E-GEOD-6400
mannitol
1
E-GEOD-6400
12 more value(s).


Biopsy tissue

studied in E-GEOD-5851

Factor Value U/D Experiments
bone
1
E-GEOD-5851


Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd38
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-6710, E-GEOD-19348, E-MEXP-1251, ... (10 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-MEXP-2359, E-MEXP-2283, E-MTAB-62 ... (5 experiments)

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-89, E-GEOD-19743, E-TABM-147, E-GEOD-21138

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-20847, E-MEXP-2340

Genotype
studied in E-GEOD-2466, E-GEOD-21750, E-TABM-321, E-TABM-868, E-TABM-601, ... (6 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-TABM-127, E-GEOD-20504, E-MEXP-1446, E-GEOD-19018, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 status
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-TABM-176, E-GEOD-1926, E-GEOD-6919, ... (24 experiments)

Infection
studied in E-MEXP-1274, E-MEXP-561

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-7819, E-GEOD-21750, E-GEOD-1657, E-GEOD-2487

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Progression free survival of days
studied in E-GEOD-5851

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19246

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-MEXP-548, E-MEXP-2759 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-1643, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Stimulus or stress
studied in E-GEOD-7538

Strain or line
studied in E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

tissue (organ)
studied in E-GEOD-22601

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-MEXP-973, E-GEOD-13818, ... (6 experiments)

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Processing time: 0.428 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM